16 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
.
“2023 was a momentous year for Verve as we made significant strides towards our mission of protecting the world from cardiovascular disease. Our
8-K
EX-99.1
VERV
Verve Therapeutics Inc
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
to rapidly submit our IND upon completion. This is a momentous year as we continue our mission of transforming the treatment of cardiovascular disease
10-K
2021 FY
VERV
Verve Therapeutics Inc
14 Mar 22
Annual report
7:04am
around us to do the same.
Passion: we are motivated by our mission to reimagine the approach to the treatment of CVD for patients and their families … inspections, such as foreign pre-approval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed
8-K
EX-99.1
cui94s
12 Aug 21
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
8:20am
424B4
655 qdcyz51i869y7ri
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
ioi9 6x00q4n
14 Jun 21
IPO registration (amended)
6:15am
S-1
18191rp u7m6ss8z
28 May 21
IPO registration
4:04pm
S-1
EX-10.15
x2c6 vagung
28 May 21
IPO registration
4:04pm
S-1
EX-10.16
nq5xq wczm
28 May 21
IPO registration
4:04pm
S-1
EX-10.14
j4z9k5dwbl8mzjudbw
28 May 21
IPO registration
4:04pm
DRS
EX-10.17
2mj 4hulqj
16 Apr 21
Draft registration statement
12:00am
DRS
EX-10.15
67v7 mt7qvpl3gqf
16 Apr 21
Draft registration statement
12:00am
DRS
wbrw busmgo
16 Apr 21
Draft registration statement
12:00am
DRS
EX-10.16
6pwjod 3uy0h427ct9qm
16 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next